Cipro - greco - Κυπριακή Δημοκρατία, Υπουργείο Γεωργίας, Αγροτικής Ανάπτυξης και Περιβάλλοντος, Κτηνιατρικές Υπηρεσίες

bioveta a.s. - actinobacillus pleuropneumoniae serotype 2 rp ≥ 1* actinobacillus pleuropneumoniae ορότυποι 9, 11 rp ≥ 1* ανατοξίνη apx i rp ≥ 1* ανατοξίνη apx ii rp ≥ 1* ανατοξίνη apx iii rp ≥ 1* - emulsion for injection - vaccine - pigs

Cipro - greco - Κυπριακή Δημοκρατία, Υπουργείο Γεωργίας, Αγροτικής Ανάπτυξης και Περιβάλλοντος, Κτηνιατρικές Υπηρεσίες

laboratorios hipra s.a. - ΑΔΡΑΝΟΠΟΙΗΜΈΝΟ ΚΟΥΝΈΛΙ ΑΙΜΟΡΡΑΓΙΚΉ ΝΌΣΟΣ ΤΟΥ ΙΟΎ => 500 uha - emulsion for injection - vaccine - rabbits

Cipro - greco - Κυπριακή Δημοκρατία, Υπουργείο Γεωργίας, Αγροτικής Ανάπτυξης και Περιβάλλοντος, Κτηνιατρικές Υπηρεσίες

neocell ΕΠΕ - rotavirus suis inactivated escherichia coli inactivated f4 (o 147:k88 ab, o 149:k88 ac) f5 (o 101:k99) f5,f41 (o 101:k99:f41) f6 (8429 k85:987p) - emulsion for injection - vaccine - pigs

Cipro - greco - Κυπριακή Δημοκρατία, Υπουργείο Γεωργίας, Αγροτικής Ανάπτυξης και Περιβάλλοντος, Κτηνιατρικές Υπηρεσίες

laboratorios hipra s.a. - Αδρανοποιημένο Χλαμύδια abortus στέλεχος a22 Αδρανοποιημένο salmonella enterica subsp. enterica serovar abortusovis στέλεχος sao - suspension for injection - vaccine - sheep

Unione Europea - greco - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - Χοίροι - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Unione Europea - greco - EMA (European Medicines Agency)

ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - Ανοσολογικά για τις αρουραίους - Χοίροι - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.

Grecia - greco - Εθνικός Οργανισμός Φαρμάκων

sanofi pasteur, lyon, france 14 espace henry vallee, 69007 lyon - hepatitis a, virus, purified inactivated - inj.su.pfs (ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ ΣΕ ΠΡΟΓΕΜΙΣΜΕΝΗ ΣΥΡΙΓΓΑ) - 80eu/0.5ml - hepatitis a, virus, purified inactivated 80eu - hepatitis a, inactivated, whole virus

Unione Europea - greco - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - Χοίροι - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Unione Europea - greco - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - Ανοσολογικά για τις αρουραίους - Χοίροι (πάχυνσης) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Unione Europea - greco - EMA (European Medicines Agency)

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - Ανοσολογικά για τα ιπποειδή - Αλογα - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.